In all of these relapsed cases, sensitivity to repeat TKI therapy was maintained, suggesting the existence of CML stem cells that are independent of BCR::ABL signaling and viable within the bone marrow microenvironment even under conditions of long-term remission [137,138]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.